GSA Capital Partners LLP Increases Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Key Points

• GSA Capital Partners LLP increased its holdings in Xeris Biopharma by 178.3% during the first quarter, acquiring an additional 88,892 shares.
• Xeris Biopharma's stock rose 5.7%, currently trading at $5.38, with a market cap of $841.32 million.
• Analysts have provided mixed ratings on Xeris, with Oppenheimer raising the price target to $7.00 while Wall Street Zen downgraded the stock to a "hold" rating.

GSA Capital Partners LLP lifted its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 178.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 138,735 shares of the company's stock after buying an additional 88,892 shares during the period. GSA Capital Partners LLP owned about 0.09% of Xeris Biopharma worth $762,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Federated Hermes Inc. increased its stake in Xeris Biopharma by 36,542.7% in the 1st quarter. Federated Hermes Inc. now owns 687,783 shares of the company's stock worth $3,776,000 after purchasing an additional 685,906 shares during the period. Essex Investment Management Co. LLC raised its holdings in shares of Xeris Biopharma by 53.8% during the first quarter. Essex Investment Management Co. LLC now owns 730,444 shares of the company's stock valued at $4,010,000 after acquiring an additional 255,489 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in Xeris Biopharma by 9.4% in the first quarter. Mackenzie Financial Corp now owns 142,104 shares of the company's stock valued at $780,000 after acquiring an additional 12,152 shares in the last quarter. Cetera Investment Advisers purchased a new position in Xeris Biopharma during the 1st quarter valued at $245,000. Finally, Legato Capital Management LLC increased its position in Xeris Biopharma by 52.9% during the 1st quarter. Legato Capital Management LLC now owns 217,318 shares of the company's stock valued at $1,193,000 after purchasing an additional 75,154 shares during the period. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Stock Performance

NASDAQ XERS traded down $0.04 on Wednesday, hitting $5.45. 1,399,850 shares of the stock were exchanged, compared to its average volume of 2,426,072. The stock has a fifty day moving average price of $4.87 and a two-hundred day moving average price of $4.52. The firm has a market capitalization of $851.49 million, a P/E ratio of -18.24 and a beta of 0.65. Xeris Biopharma Holdings, Inc. has a 52-week low of $2.10 and a 52-week high of $6.07.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. Sell-side analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Kevin Mcculloch bought 25,000 shares of the company's stock in a transaction that occurred on Friday, June 13th. The shares were purchased at an average price of $4.38 per share, for a total transaction of $109,500.00. Following the completion of the transaction, the insider directly owned 1,708,585 shares in the company, valued at approximately $7,483,602.30. This represents a 1.48% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.56% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

XERS has been the topic of a number of research analyst reports. Oppenheimer boosted their price objective on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Wall Street Zen downgraded shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $6.25.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.